Stockscreener 앱 받기
0.84
8.43%
0.0653
시장 영업 전:
.78
-0.06
-7.14%
전일 마감가:
$0.7747
열려 있는:
$0.7747
하루 거래량:
92,377
Relative Volume:
0.55
시가총액:
$13.09M
수익:
$9.37M
순이익/손실:
$-8.45M
주가수익비율:
-1.037
EPS:
-0.81
순현금흐름:
$-7.27M
1주 성능:
+8.44%
1개월 성능:
-13.40%
6개월 성능:
-53.33%
1년 성능:
-46.15%
1일 변동 폭
$0.732
$0.85
1주일 범위
$0.6944
$0.85
52주 변동 폭
$0.57
$3.62
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
명칭
Bioaffinity Technologies Inc
전화
210-698-5334
주소
22211 WEST INTERSTATE-10, SAN ANTONIO
BIAF을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
0.84 | 13.09M | 9.37M | -8.45M | -7.27M | -0.81 |
|
TMO
Thermo Fisher Scientific Inc
|
572.71 | 219.06B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
210.01 | 151.02B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
147.64 | 42.12B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
209.96 | 38.11B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
460.56 | 37.71B | 3.84B | 866.24M | 792.60M | 10.37 |
Bioaffinity Technologies Inc 주식(BIAF)의 최신 뉴스
Zacks Initiates Coverage of bioAffinity With Neutral Recommendation - MSN
The Zacks Analyst Blog Highlights Amazon, Bank of America, Caterpillar, NVE and bioAffinity - Yahoo Finance
Top Research Reports for Amazon.com, Bank of America & Caterpillar - Yahoo Finance
bioAffinity Technologies (NASDAQ:BIAFW) Trading Down 16.7% – Here’s Why - Defense World
Global Drug Screening Market Is Forecasted to Reach $19.5 Billion By 2029 - GlobeNewswire
Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
bioAffinity Technologies (BIAF) Stock Price, News & Analysis - MarketBeat
BIOAFFINITY TECHNOLOGIES, INC. : Other Events, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
bioAffinity Technologies secures Australian patent for ‘CyPath Lung’ spit test - Mugglehead
bioAffinity secures Australian patent for lung cancer test - MSN
bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic - BioSpace
bioAffinity Technologies stock hits 52-week low at $0.65 - MSN
Biotech company CEO receives pay bump - San Antonio Business Journal
bioAffinity Technologies Increases CEO Maria Zannes’ Annual Base Salary to $300,000 - Defense World
bioAffinity Technologies Adjusts CEO Compensation Package - TipRanks
bioAffinity Technologies CEO receives salary increase - Investing.com
bioAffinity Technologies (NASDAQ:BIAFW) Trading Up 4.7% – Time to Buy? - Defense World
bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung - BioSpace
bioAffinity's Breakthrough Lung Cancer Test Shows 92% Accuracy, Could Save Medicare $379M - StockTitan
Enlivex CEO to Showcase Breakthrough Allocetra Cell Therapy on Bloomberg TV Special Feature - StockTitan
**bioAffinity Technologies Reports Results of 2024 Special Meeting** - Defense World
bioAffinity Technologies (NASDAQ:BIAF) Shares Down 2% – Here’s Why - Defense World
bioAffinity Technologies Boosts Sales with CyPath Lung - Yahoo Finance
bioAffinity Technologies (NASDAQ:BIAFW) Trading Down 25.7% – Time to Sell? - Defense World
San Antonio biotech company looks to expand in 2025 - The Business Journals
bioAffinity Tech to Showcase Breakthrough Lung Cancer Detection Test in Exclusive Investor Webinar - StockTitan
Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19 - Business Wire
Flow Cytometry in Oncology Market is Likely to Increase At - openPR
bioAffinity Technologies stock hits 52-week low at $0.91 By Investing.com - Investing.com UK
William Bauta to Spearhead Product Development at bioAffinity Technologies - MPO-mag
bioAffinity Technologies Set for Continued Expansion in 2025 - BioSpace
BioAffinity Technologies Set for Continued Expansion in 2025 - Marketscreener.com
bioAffinity's CyPath® Lung Test Drives Explosive 1,750% Sales Growth; Projects Strong 2024 Revenue - StockTitan
bioAffinity Technologies Adds Japanese Patent to its IP Portfolio - MPO-mag
bioAffinity Technologies stock hits 52-week low at $1.03 By Investing.com - Investing.com UK
Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule - Business Wire
bioAffinity Technologies (NASDAQ:BIAFW) Stock Price Up 24.4% – Here’s What Happened - Defense World
BioAffinity Technologies files to sell 2.72M shares of common stock for holders - Nasdaq
bioAffinity Technologies stock hits 52-week low at $1.21 By Investing.com - Investing.com UK
BioAffinity Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Earnings roundup: Rackspace struggles as Victory Capital surges - San Antonio Express-News
bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024 - Zenopa
bioAffinity Technologies Reports Strong Q3 Growth - TipRanks
bioAffinity Technologies stock hits 52-week low at $1.24 By Investing.com - Investing.com Canada
Bioaffinity Technologies Inc (BIAF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.51%
자본화:
|
볼륨(24시간):